NeoGenomics announces launch of Neo Comprehensive CGPs

NeoGenomics announced the expansion of their next-generation sequencing portfolio of products with the commercial availability of multiple tests, including Neo Comprehensive – Solid Tumor, a comprehensive genomic profile for solid tumor cancers, and Neo Comprehensive – Myeloid Disorders, a CGP for myeloid neoplasms. Neo Comprehensive – Solid Tumor is NeoGenomics’ largest solid tumor, pan cancer assay available to date. This CGP detects genomic alterations that are most relevant in diagnosis, therapy selection, prognosis and clinical trials. The panel includes 517 genes by both DNA and RNA NGS, microsatellite instability, and tumor mutational burden. With this test comes an improved turnaround time and a streamlined test report format. Neo Comprehensive – Myeloid Disorders is available as an enhancement of NeoGenomics’ previous Myeloid panel, making it the largest DNA and RNA NGS myeloid panel on the market with the most clinically actionable features, including single nucleotide variants, copy number variants, insertions and deletions, and fusions. In parallel with the two product launches, NeoGenomics is also introducing two software resources to complement their testing menu: NeoAccess, a test requisitioning tool which includes clinical decision support, up-front patient benefits check and prior authorization assistance abilities; and NeoSeek, a platform that allows clinicians the ability to mine their previous testing data to identify their patients who may be biomarker eligible for a new therapy or clinical trial.